A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

被引：0
|
作者：
Murthy, Guru Subramanian Guru [1 ]
Shah, Bijal D. [2 ]
Duvall, Adam S. [3 ]
Leonard, Jessica T. [4 ]
Badar, Talha [5 ]
Yi, Cecilia Y. Arana [6 ]
Kearl, Tyce [7 ]
Baim, Arielle [8 ]
Harrington, Alexandra M. [8 ]
Szabo, Aniko [8 ]
Atallah, Ehab L. [9 ]
机构：
[1] Med Coll Wisconsin, Div Hematol Oncol, Dept Med, Milwaukee, WI USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Univ Chicago, Dept Med, Chicago, IL USA
[4] Oregon Hlth & Sci Univ, Dept Hematol & Med Oncol, Portland, OR USA
[5] Mayo Clin, Jacksonville, FL USA
[6] Mayo Clin, Hematol Oncol, Scottsdale, AZ USA
[7] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA
[8] Med Coll Wisconsin, Milwaukee, WI USA
[9] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187468
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
    Zhang, Mingzhi
    Chen, Dan
    Fu, Xiaorui
    Meng, Huimin
    Nan, Feifei
    Sun, Zhenchang
    Yu, Hui
    Zhang, Lei
    Li, Ling
    Li, Xin
    Wang, Xinhua
    Wang, Min
    You, Fengtao
    Li, Zhaoming
    Chang, Yu
    Zhou, Zhiyuan
    Yan, Jiaqin
    Li, Jiwei
    Wu, Xiaolong
    Wang, Yu
    Wang, Yinyan
    Xiang, Shufen
    Chen, YuSheng
    Pan, Guifang
    Xu, Hanying
    Zhang, Bozhen
    Yang, Lin
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2830 - 2843
  • [42] Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    Wang, Ying
    Yin, Qingsong
    Ren, Jinhai
    Zhou, Hongsheng
    Gong, Tiejun
    Zhu, Feng
    Zhang, Xi
    Wen, Qin
    Mei, Heng
    Huang, Wei
    Li, Haiying
    Wang, Jianxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
    von Stackelberg, Arend
    Locatelli, Franco
    Zugmaier, Gerhard
    Handgretinger, Rupert
    Trippett, Tanya M.
    Rizzari, Carmelo
    Bader, Peter
    O'Brien, Maureen M.
    Brethon, Benoit
    Bhojwani, Deepa
    Schlegel, Paul Gerhardt
    Borkhardt, Arndt
    Rheingold, Susan R.
    Cooper, Todd Michael
    Zwaan, Christian M.
    Barnette, Phillip
    Messina, Chiara
    Michel, Gerard
    DuBois, Steven G.
    Hu, Kuolung
    Zhu, Min
    Whitlock, James A.
    Gore, Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4381 - +
  • [44] Preliminary Biomarker and Pharmacokinetic-Response Relationships in a Phase 1 Study of AMG 330, a Bispecific CD33 T-Cell Engager (BiTE®) Antibody Construct, in Patients (PTS) with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Dos Santos, C. E.
    Anderson, A.
    Yago, M.
    Lesley, R.
    Stein, A.
    Walter, R.
    Lutteropp, M.
    Yang, Z.
    Mehta, B.
    Subklewe, M.
    Ravandi, F.
    ANNALS OF HEMATOLOGY, 2019, 98 : S58 - S59
  • [45] Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
    Aldoss, Ibrahim
    Tizro, Parastou
    Bedi, Davsheen
    Mangan, James K.
    Clark, Mary C.
    Spencer, David
    Song, Joo Y.
    Cherian, Sindhu
    Pillai, Raju
    Kim, Young
    Mahajan, Nitin
    Gendzekhadze, Ketevan
    James, Mike
    Jacobs, Kenneth
    Davidson-Moncada, Jan
    Forman, Stephen J.
    Wang, Huan-You
    Afkhami, Michelle
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 3511 - 3516
  • [46] A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
    Ishitsuka, Kenji
    Utsunomiya, Atae
    Katsuya, Hiroo
    Takeuchi, Shogo
    Takatsuka, Yoshifusa
    Hidaka, Michihiro
    Sakai, Tatsunori
    Yoshimitsu, Makoto
    Ishida, Takashi
    Tamura, Kazuo
    CANCER SCIENCE, 2015, 106 (09): : 1219 - 1223
  • [47] PHASE I STUDY OF MOXETUMOMAB PASUDOTOX IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
    Ravandi, F.
    Cortes, J.
    Thomas, D.
    Rytting, M.
    Daver, N.
    Konopleva, M.
    Kebriaei, P.
    Wierda, W.
    DiNardo, C.
    Bivins, C.
    Mccue, D.
    Pierce, S.
    Richie, A.
    Kantarjian, H.
    HAEMATOLOGICA, 2016, 101 : 351 - 351
  • [48] Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis
    Meghavi Kathpalia
    Pinki Mishra
    Ram Bajpai
    Dinesh Bhurani
    Nidhi Agarwal
    Annals of Hematology, 2022, 101 : 1655 - 1666
  • [49] Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis
    Kathpalia, Meghavi
    Mishra, Pinki
    Bajpai, Ram
    Bhurani, Dinesh
    Agarwal, Nidhi
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1655 - 1666
  • [50] Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
    Liang, Zuyu
    Cui, Jiazhen
    Chang, Alex Hongsheng
    Yu, Jian
    Hu, Yongxian
    Huang, He
    REGENERATIVE THERAPY, 2020, 15 : 281 - 284
12345